Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.35 |
| ▸ | AGXT | P21549 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.34 |
| ▸ | PRNP | P04156 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6521013 | 0.83 | CYP2C9 (0.42) | MAPK14SLC2A1CYP11B1CYP11B2TRPA1 | |
| Hydrochloric Acid SCHEMBL6517808 | 0.82 | CYP2C9 (0.41) | MAPK14SLC2A1CYP11B1CYP11B2TRPA1 | |
| SCHEMBL3427891 | 0.81 | NR1H4 (0.47) | SLC2A1KDM4ESMN1; SMN2NR1H4 | |
| SCHEMBL6523043 | 0.78 | CYP11B2 (0.54) | MAPK14SLC2A1CYP11B1CYP11B2TRPA1 | |
| SCHEMBL6520517 | 0.74 | MAPK14 (0.37) | MAPK14SLC2A1CYP11B1CYP11B2TRPA1 | |
| SCHEMBL6523534 | 0.73 | SLC2A1 (0.39) | SLC2A1CYP11B1CYP11B2KDM4ENR1H4 | |
| SCHEMBL6524569 | 0.71 | DHODH (0.43) | MAPK14CYP11B1CYP11B2TRPA1 | |
| SCHEMBL220095 | 0.71 | CYP11B1 (0.39) | MAPK14SLC2A1CYP11B1CYP11B2TRPA1 | |
| SCHEMBL3431716 | 0.70 | NR4A2 (0.47) | SLC2A1AGXT | |
| SCHEMBL3435404 | 0.69 | NR1H4 (0.36) | SLC2A1KDM4ENR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262769-B1 | POLYSUBSTITUTED 2-ARYL-6-PHENYL-IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-11-05 | — | — | EP | disclosed |
| US-20110065745-A1 | POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065745-A1 | POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF | JAK2, ABL1, REN | MAPK14 3032/4885SLC2A1 986/4885CYP11B1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.